Actively Recruiting

Age: 18Years +
All Genders
ID03717844

Registry for Adults With Plasma Cell Disorders (PCD's)

Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2025-11-20

2000

Participants Needed

1

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are creating a registry of patients with plasma cell disorders (PCDs), such as multiple myeloma, to collect detailed assessments over time. The study aims to understand patient care patterns and satisfaction with these assessments, and to support future research in this patient group. An optional blood sample may be collected to study a genetic aging marker called p16INK4a. Participants complete a comprehensive assessment at the start and at regular intervals afterward. This assessment covers their ability to live independently, other medical conditions, cognitive and psychological health, social support, medications, and nutrition. Researchers also review patients' medical records to gather more information. During the study, patients are asked to complete questionnaires and assessments repeatedly to track changes over time. The primary outcomes include building the registry and completing these assessments over ten years. Secondary outcomes focus on patient response rates to the assessment and their satisfaction. The study is observational and involves no experimental treatments, with participation lasting up to ten years.

CONDITIONS

Brief Title

Registry for Adults With Plasma Cell Disorders (PCD's)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients have an outpatient or inpatient appointment at UNC Cancer Hospitals or affiliated clinics for evaluation and management of a plasma cell disorder.
  • Patients have a documented diagnosis of a plasma cell disorder, including conditions such as multiple myeloma, amyloidosis, Castleman's disease, POEMS syndrome, and others.
  • Age 18 years or older.
  • Must consent to participate and agree to complete assessments at baseline and follow-up.
  • Must be able to read and speak English.
Not Eligible

You will not qualify if you...

  • Physical or psychiatric illnesses or problems that, in the treating clinician's judgment, would prevent successful participation in the study.
  • No imaging or lab studies are required to determine eligibility.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 10 years

Participants complete a baseline multi-dimensional assessment of their functional status, co-morbid medical conditions, cognition, psychological status, social functioning and support, medication review, and nutritional status. Assessments are repeated over time to monitor their health and support future research.

Baseline assessment and follow-up assessments over time

Trial Site Locations

Total: 1 location

1

North Carolina Cancer Hospital

Chapel Hill, North Carolina, United States, 27599

Actively Recruiting

Loading map...

Research Team

N

Nicholas Mangieri

K

Kendall Conder

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multi...

Multiple Myeloma

Actively Recruiting

1 location

Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematolog...

Multiple Myeloma

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here